Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 9/30/2020 | 6/30/2020 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.019 | -0.015 | 0.004 | -0.01 |
| % Growth | -26% | -448.8% | 143% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |